Special Issue "Biomarkers, Therapeutic Opportunities and Tumor Microenvironment in Solid and Hematological Tumors: Past, Present, and Future"
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 2176
Interests: international collaborations for research; surgical pathology; gynecological pathology; uropathology; gastrointestinal pathology; salivary gland pathology; molecular pathology; parasitic and infectious diseases
Interests: next-generation sequencing; predictive markers in solid tumors; molecular pathology
Special Issues, Collections and Topics in MDPI journals
Special Issue in Diagnostics: Next-Generation Sequencing in Tumor Diagnosis and Treatment II
Special Issue in International Journal of Molecular Sciences: Circulating Molecules and Precision Medicine in Cancer
Special Issue in Diagnostics: Tissue-Based Biomarkers of Solid Tumors in the Routine Clinical Setting 2.0
Interests: gynecological pathology and cytology; molecular and computational pathology; pathology informatics
Molecular analysis and tissue biomarkers play a fundamental role in cancer diagnosis, prognosis and treatment. Continuous efforts need to be devoted to finding new diagnostic, prognostic and predictive targeted markers to identify novel therapeutic approaches, which will help to guide clinical therapeutic decision making.
The "tumor microenvironment" (TMA) is a continuously evolving entity. Its complex and dynamic system includes the set of molecules (cytokines, chemokines, etc.), inflammatory and mesenchymal cells or other tissue structures (e.g., lymphocytes, macrophages, stromal cells/fibroblasts, fat cells, blood vessels, etc.) which constantly interact with tumor cells, influencing their growth and spread.
Acting on the TMA is one of the treatment strategies used to contain neoplastic progression. Immune checkpoint inhibitors (ICIs) (such as anti-PD-1, anti-PD-L1 and anti-CTLA4 drugs) target the homeostasis regulators of adaptive immunity and seem effective in the more immunogenic TMA. Various TMA components may contribute to the development of resistance to treatment in multiple solid and hematological tumor histotypes.
This Special Issue aims to present a collection of experimental studies, review articles and other types of clinic–pathologic studies that summarize the state of the art and/or provide new insights into the role of molecular/tissue biomarkers, TMA and/or new therapeutic approaches in solid and hematological tumors, dealing with unanswered questions and analyzing future perspectives.
Dr. Andrea Palicelli
Dr. Dario De Biase
Dr. Aleksandra Asaturova
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- genetic/epigenetic landscape
- molecular analysis
- immune system
- tumor-infiltrating lymphocytes
- immune checkpoint inhibitors